Organon & Co. Announces Quarterly Dividend of $0.28 (NYSE:OGN)

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Thursday, May 2nd, Zacks reports. Shareholders of record on Monday, May 13th will be given a dividend of 0.28 per share on Thursday, June 13th. This represents a $1.12 annualized dividend and a yield of 5.49%. The ex-dividend date is Friday, May 10th.

Organon & Co. Stock Performance

Shares of NYSE:OGN opened at $20.40 on Wednesday. The company has a market capitalization of $5.25 billion, a PE ratio of 5.08, a price-to-earnings-growth ratio of 0.88 and a beta of 0.81. The stock has a fifty day moving average of $18.25 and a 200-day moving average of $15.79. Organon & Co. has a one year low of $10.84 and a one year high of $24.08.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 15th. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. Organon & Co. had a negative return on equity of 259.73% and a net margin of 16.50%. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.55 billion. As a group, research analysts forecast that Organon & Co. will post 4.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Piper Sandler upped their price objective on shares of Organon & Co. from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Monday, April 29th. The Goldman Sachs Group lifted their price target on Organon & Co. from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Friday, May 3rd.

Insiders Place Their Bets

In related news, insider Kirke Weaver purchased 2,720 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was bought at an average price of $18.36 per share, for a total transaction of $49,939.20. Following the purchase, the insider now owns 15,181 shares in the company, valued at approximately $278,723.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.17% of the company’s stock.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.